Many proteins that drive cancer are considered “undruggable” because they lack the pockets that conventional drugs need to bind and block them. A new approach in prostate cancer attempts to bypass this problem: instead of inhibiting a cancer-driving protein, make the cell destroy it. Researchers have developed a protein degrader (against an undisclosed protein) believed […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! This week is focused mainly on clinical research. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical Research Phase 1 Trial: IL-18–Armored STEAP1 […]
Prostate cancer does not develop in the same way in every patient. Different biological processes can damage the DNA of cancer cells, leaving behind characteristic patterns, or “mutational signatures.” A recent study, published on Nature, used whole-genome sequencing to combine these patterns and identify eight integrated mutational footprints (IMFs), providing a broader picture of how […]
Tinengotinib (TT-00420), a multikinase inhibitor with a distinctive target profile, is showing early signals in metastatic castration‑resistant prostate cancer (mCRPC), a setting where options after modern androgen‑receptor pathway inhibitors and taxanes remain limited. Results from a US‑based, multicenter phase 1/2 trial, published in Clinical Cancer Research, reported an objective response rate of 33.3% in a […]
A multicentre, randomised trial published in The Lancet Oncology shows that a supervised, behaviourally supported lifestyle programme can measurably blunt the adverse effects of androgen deprivation therapy (ADT) for prostate cancer. Called STAMINA, the study enrolled 700 men on ADT across 15 NHS trusts in England and randomly assigned them in a 5:4 ratio to […]
A new cohort study published in JAMA Network provides some of the most detailed evidence to date on how the type of fat men eat after a prostate cancer diagnosis relates to long-term survival. The analysis, based on 4,884 participants in the Health Professionals Follow-Up Study followed for a median of 12.8 years, shows that […]
IL‑18–armored STEAP1 CAR T cells represent a biologically rational, early‑clinical strategy that combines a well‑validated prostate‑cancer target with next‑generation cytokine armoring designed to overcome the hostile tumour microenvironment and antigen heterogeneity that have limited earlier immunotherapy efforts. STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) was first identified in advanced prostate cancer and is now […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! No rest for the weekend! Some new promising trials and preclinical research for us. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. Clinical […]
For men with metastatic prostate cancer, the current standard is continuous androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) such as abiraterone, enzalutamide, apalutamide, or darolutamide. This approach improves survival but comes with substantial clinical and financial toxicity: fatigue, metabolic changes, sexual dysfunction, bone loss, cardiovascular risk, and long‑term treatment costs. The […]
A new phase 3 clinical trial is preparing to evaluate risvutatug rezetecan, or Ris-Rez or GSK5764227, in men with metastatic castration-resistant prostate cancer (mCRPC), an advanced form of prostate cancer that continues to progress despite androgen-deprivation treatment. The study, called EMBOLD Prostate-302, will compare this experimental therapy with best supportive or standard care, potentially including the […]